Business Context and Reporting Period
This Form 8-K Current Report was filed by CytoSorbents Corporation on December 12, 2019, regarding events occurring on December 9, 2019. The filing addresses the departure of a senior officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to a specific severance payment:
- Separation Payment: $118,650 (lump sum, less applicable taxes and withholdings).
- Payment Timing: Payable on or after January 1, 2020, and before January 30, 2020.
- Health Benefits: Company to pay employer premium percentage contribution for COBRA coverage for up to 12 months, subject to eligibility.
Material Changes
The primary material change is the departure of Dr. Eric Mortensen from his position as Chief Medical Officer, effective December 31, 2019. This follows a previously announced departure.
Outlook, Risks, and Unusual Items
The filing details the execution of a Separation Agreement and Release. Key terms include:
- Customary confidentiality, cooperation, and non-disparagement covenants.
- A general release of claims by the departing officer.
- Continuation of health benefits under COBRA for a 12-month period, contingent on the officer not qualifying for coverage under another employer plan.
The filing does not contain forward-looking guidance, general risk factors, or discussion of unusual items beyond the executive departure.
Investor Verification Checklist
- Verify the effective date of Dr. Mortensen's departure (December 31, 2019).
- Confirm the total cash liability of $118,650 and the payment window (January 1–30, 2020).
- Review the full Separation Agreement and Release filed as Exhibit 10.1 for detailed covenants.
- Monitor for the appointment of a new Chief Medical Officer to fill the vacancy.